You are here

Articles

ARIAD Announces the Commercial Availability of Iclusig (Ponatinib) for Patients with Refractory Philadelphia-Positive Leukemias in the U.S.

published: 17 January 2014

Bone Marrow Microenvironment Could Offer Future Target in CML

published: 9 January 2014

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.

published: 2 January 2014

Penn Medicine Team Reports Findings from Research Study

published: 9 December 2013

ASH 2013: CML Relevant Abstracts

published: 3 December 2013

Ariad gets positive CHMP opinion for continued Iclusig (ponatinib) availability

published: 22 November 2013

Safety and efficacy of imatinib cessation for CML patients with stable undetectable MRD: results from the TWISTER Study

published: 19 November 2013

European Medicines Aagency- PRAC update on use of ponatinib -Iclusig

published: 12 November 2013

Bone Drug Kills Leukemia in Mice

published: 4 November 2013

Ponatinib Manufacturer Suspends Distribution

published: 1 November 2013

FDA Drug Safety Communication: FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales

published: 1 November 2013

Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring.

published: 20 October 2013

ARIAD Announces Discontinuation of the Phase 3 Epic Trial of Iclusig in Patients with Newly Diagnosed Chronic Myeloid Leukemia

published: 18 October 2013

Iclusig (Ponatinib): FDA Drug Safety Communication

published: 17 October 2013

ARIAD Announces Changes in the Clinical Development Program of Iclusig

published: 10 October 2013

Treatment of Chronic Myeloid Leukemia: Frontline Therapy

published: 27 September 2013

Cleavage of BCR–ABL transcripts at the T315I point mutation by DNAzyme promotes cell death in imatinib-resistant BCR–ABL cells

published: 7 August 2013

Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells

published: 29 July 2013

Imatinib Discontinuation in Chronic Phase CML Doesn’t Always Lead to Relapse

published: 26 July 2013

State of CML Treatments

published: 26 July 2013